Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × Pam2CSK4 acetate and ODN M362 combination × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Diseases 1

Interventions

Cyclophosphamide 30 Radiotherapy 21 Cisplatin 21 fludarabine 19 Paclitaxel 19 Nivolumab 17 Magnetic Resonance Spectroscopy 16 Carboplatin 16 pembrolizumab 15 fludarabine phosphate 14 Specimen Handling 14 Gemcitabine 14 Biopsy 12 Radiation 11 Docetaxel 10 Cytarabine 10 Radiosurgery 9 Melphalan 9 Filgrastim 9 Etoposide 9 Doxorubicin 9 Dexamethasone 9 Ipilimumab 8 Granulocyte Colony-Stimulating Factor 8 venetoclax 7 trametinib 7 ibrutinib 7 durvalumab 7 Sorafenib 7 Rituximab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03097796 2023-04-27

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

Pulmotect, Inc.

Phase 1 Withdrawn

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡